Autor Tema: Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.  (Leído 956 veces)

0 Usuarios y 1 Visitante están viendo este tema.

Desconectado 9delta

  • Moderador General
  • Erudito de la vaporización
  • ******
  • Join Date: Feb 2011
  • Mensajes: 5.094
  • Liked: 51
  • Reputación: +755/-10
  • Vaporizar es salud
Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.
You are not allowed to view links. Register or Login, You are not allowed to view links. Register or Login, You are not allowed to view links. Register or Login, You are not allowed to view links. Register or Login, You are not allowed to view links. Register or Login, You are not allowed to view links. Register or Login, You are not allowed to view links. Register or Login, You are not allowed to view links. Register or Login, You are not allowed to view links. Register or Login.


Source

Department of Anesthesia, McGill University, Montréal, Que. mark.ware@muhc.mcgill.caAbstractBACKGROUND: Chronic neuropathic pain affects 1%-2% of the adult population and is often refractory to standard pharmacologic treatment. Patients with chronic pain have reported using smoked cannabis to relieve pain, improve sleep and improve mood.METHODS: Adults with post-traumatic or postsurgical neuropathic pain were randomly assigned to receive cannabis at four potencies (0%, 2.5%, 6% and 9.4% tetrahydrocannabinol) over four 14-day periods in a crossover trial. Participants inhaled a single 25-mg dose through a pipe three times daily for the first five days in each cycle, followed by a nine-day washout period. Daily average pain intensity was measured using an 11-point numeric rating scale. We recorded effects on mood, sleep and quality of life, as well as adverse events.RESULTS: We recruited 23 participants (mean age 45.4 [standard deviation 12.3] years, 12 women [52%]), of whom 21 completed the trial. The average daily pain intensity, measured on the 11-point numeric rating scale, was lower on the prespecified primary contrast of 9.4% v. 0% tetrahydrocannabinol (5.4 v. 6.1, respectively; difference = 0.7, 95% confidence interval [CI] 0.02-1.4). Preparations with intermediate potency yielded intermediate but nonsignificant degrees of relief. Participants receiving 9.4% tetrahydrocannabinol reported improved ability to fall asleep (easier, p = 0.001; faster, p < 0.001; more drowsy, p = 0.003) and improved quality of sleep (less wakefulness, p = 0.01) relative to 0% tetrahydrocannabinol. We found no differences in mood or quality of life. The most common drug-related adverse events during the period when participants received 9.4% tetrahydrocannabinol were headache, dry eyes, burning sensation in areas of neuropathic pain, dizziness, numbness and cough.CONCLUSION: A single inhalation of 25 mg of 9.4% tetrahydrocannabinol herbal cannabis three times daily for five days reduced the intensity of pain, improved sleep and was well tolerated. Further long-term safety and efficacy studies are indicated. (International Standard Randomised Controlled Trial Register no. ISRCTN68314063).




El documento en el link: You are not allowed to view links. Register or Login
(Sorry, but you are not allowed to access the gallery)
(click to show/hide)